Teva Stock Hits Decade High After FDA Approves Schizophrenia Drug
Translated & summarized from Globes by baba
Teva Pharmaceutical Industries' stock reached a decade high after the FDA approved its new monthly injectable schizophrenia drug, WELTRUZA, with peak sales projected at $2 billion. Separately, Similarweb is seeking shareholder approval for its incoming CEO Michael Ackerman's compensation package, including a $500,000 signing bonus and significant equity. In contrast, Nova's stock has fallen sharply from its June peak after Citi downgraded its rating, citing a need for selective stock investments.
The story in 6 lines · by baba
- Teva's stock hit a decade high after FDA approval for its new schizophrenia drug WELTRUZA.
- WELTRUZA is the first and only monthly injectable treatment for adult schizophrenia.
- Similarweb's incoming CEO Michael Ackerman faces a shareholder vote on his compensation package.
- Nova's stock has fallen 41.7% from its June peak following a Citi downgrade.
- Teva projects peak annual sales of $1.5-2 billion for WELTRUZA.
- Similarweb's stock rose 7.4% on Friday, nearing an $800 million market valuation.
Teva Pharmaceutical Industries' stock surged 4.7% on Friday, reaching a new annual high of $41.10 on the New York Stock Exchange. This price point, last seen in November 2016, reflects a market capitalization of $47.9 billion. The significant jump followed the U.S. Food and Drug Administration's (FDA) approval of WELTRUZA (Olanzapine), a novel monthly injectable treatment for adult schizophrenia. Teva highlighted that clinical trials demonstrated WELTRUZA's efficacy in improving symptoms, reducing severity, and enhancing social and personal functioning. The company projects peak annual sales for the drug to reach between $1.5 billion and $2 billion. Dr. Erick Yus, Teva's Senior Vice President for Global R&D and Chief Medical Officer, stated that the approval underscores Teva's patient-focused innovation and its ability to deliver meaningful solutions, noting WELTRUZA's scientific basis and formulation innovation that eliminates the need for post-injection monitoring.
Meanwhile, Similarweb announced its incoming CEO, Michael Ackerman, will receive a base salary of $550,000, a potential annual bonus of up to $550,000, and a one-time signing bonus of $500,000. These terms, along with equity awards totaling $10 million tied to performance and stock price milestones, require shareholder approval at a meeting scheduled for November 16. The company's board believes Ackerman possesses the necessary skills and vision for the company's next growth phase. Similarweb's stock rose 7.4% on Friday, with the company's market value approaching $800 million. The proposed compensation package places Ackerman in the 25th-50th percentile compared to similar companies, according to an external analysis.
In contrast, Nova, a semiconductor testing systems manufacturer, has seen its stock decline significantly from its June peak. After an 84.4% rise earlier in the year, Nova's stock has dropped 41.7%, resulting in a year-to-date return of 7.5%, underperforming both the U.S. semiconductor index and the Tel Aviv 35 index. This downturn follows investment bank Citi's downgrade of its recommendation for Nova from "buy" to "neutral," with a reduced price target of $415, still representing a 17.6% premium over its Nasdaq price. Citi cited a need for greater selectivity in stock picking, viewing Nova's risk-reward balance as even. Despite Citi's lower target, the average analyst price target suggests a 45.9% premium.
Mentioned
The same event, reported separately by each outlet. Open a few to compare what different newsrooms emphasize — and what they leave out.
Right 1Other 1
Not the same event — other stories that share this one’s people, places, or theme: background, reactions, and follow-ups.
